In vivo imaging of chromogranin A-positive endocrine tumours by three-step monoclonal antibody targeting

European Journal of Nuclear Medicine

Volumn 23, Issue 11, 1996, Pages 1455-1459

  Siccardi, Antonio G ^a,d   Paganelli, Giovanni ^a,c   Pontiroli, Antonio E ^a   Pelagi, Micaela ^a   Magnani, Patrizia ^a   Viale, Giovanna ^a   Faglia, Giovanni ^b   Fazio, Ferruccio ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^d DIBIT   (Italy)

Author keywords

Avidin biotin system; Chrornogranins; Endocrine tumours; Three step immunoscintigraphy; Tumour antibody targeting

Indexed keywords

AVIDIN; BIOTIN; CHROMOGRANIN A; CORTICOTROPIN; INDIUM 111; MONOCLONAL ANTIBODY; PARATHYROID HORMONE;

ARTICLE; CARCINOID; CLINICAL ARTICLE; ENDOCRINE TUMOR; HUMAN; IMMUNOSCINTIGRAPHY; INSULINOMA; INTRAVENOUS DRUG ADMINISTRATION; THYROID MEDULLARY CARCINOMA; TUMOR SCINTISCANNING;

ANTIBODIES, MONOCLONAL; CHROMOGRANIN A; CHROMOGRANINS; ENDOCRINE GLAND NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; RADIOIMMUNODETECTION; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 0029957461     PISSN: 03406997     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01254467     Document Type: Article

References (23)

1. Deftos LJ. Chromogranin A: its role in endocrine function and as an endocrine and neuroendocrine tumor marker. Endocr Rev 1991; 12: 181-187.
2. Winder H, Fischer-Colbrie R. The chromogranins A and B: the first 25 years and future perspectives. Neurosciences 1992; 49: 497-528.
3. Pelagi M, Bisiani C, Gini A, Bonardi MA, Rosa P, Marè P, Viale G, Cozzi MG, Salvadore M, Zanini A, Siccardi AG, Buffa R. Preparation and characterization of anti-human chromogranin A and chromogranin B (secretogranin I) monoclonal antibodies. Mol Cell Probes 1989; 3: 87-101.
4. Settleman J, Nolan J, Angeletti RH. Chromogranin, an integral membrane protein. J Biol Chem 1985; 260: 1641-1644.
5. Pimplikar S, Huttner WB, Chromogranin B (secretogranin I), a secretory protein of the regulated pathway, is also present in a tightly membrane-associated form in PC12 cells. J Biol Chem 1992; 267: 4110-4113.
6. Paganelli G, Riva P, Deleide G, Clivio A, Chiolerio F, Scassellati GA, Malcovati M, Siccardi AG. In vivo labelling of biotinylated monoclonal antibodies by radioactive avidin: a strategy to increase tumor radiolocalization. Int J Cancer Suppl 1988; 2: 121-125.
7. Paganelli G, Pervez S, Siccardi AG, Rowlinson G, Deleide G, Chiolerio F, Malcovati M, Scassellati GA, Epenetos AA. Intraperitoneal radio-localization of tumors pre-targeted by biotinylated monoclonal antibodies. Int J Cancer 1990; 45: 1184-1189.
8. Paganelli G, Magnani P, Zito F, Villa E, Stella M, Sudati F, Lopalco L, Rossetti C, Malcovati M, Chiolerio F, Seccamani E, Siccardi AG, Fazio F. Three-step monoclonal antibodies tumor targetting in CEA-positive patients. Cancer Res 1991; 51: 5960-5966.
9. Paganelli G, Siccardi AG, Malcovati M, Scassellati G, Fazio F. Biotinylated monoclonal antibodies: their potential for diagnosis and therapy of cancer. Curr Opin Ther Pat 1993; 3: 1465-1474.
10. Paganelli G, Magnani P, Siccardi AG, Fazio F. Clinical application of the avidin-biotin system for tumor targeting. In: Goldenberg DM, ed. Cancer therapy with radiolabeled antibodies. New York: CRC Press; 1995: 239-254.
11. Goodwin DA. Pharmacokinetics and antibodies. J Nucl Med 1987; 28: 1358-1362.
12. Paganelli G, Magnani P, Zito F, Lucignani G, Sudati F, Truci G, Motti E, Terreni M, Polio B, Giovanelli M, Canal N, Scotti G, Comi G, Koch P, Maecke HR, Fazio F. Pre-targeted immuno-detection in glioma patients: tumor localization and single photon emission tomography imaging of 99m Tc PnAO-biotin. Eur J Nucl Med 1994; 21: 314-321.
13. Dosio F, Magnani P, Paganelli G, Samuel A, Chiesa G, Fazio F. Three-step tumor pretargeting in lung cancer immunoscintigraphy. J Nucl Biol Med 1993; 37: 228-232.
14. Colombo P, Paganelli G, Magnani P, Songini C, Fazio F, Faglia G. Immunoscintigraphy with antibodies in patients with endocrine/neuroendocrine tumors. J Endocrinol Invest 1993; 16: 841-843.
15. 111In-labeled pentetreotide and three-step immuno-scintigraphy with anti-chromogranin A monoclonal antibody in the diagnosis of pituitary adenomas. Cell Biophys 1994; 24-25: 307-313.
16. Galen RS, Gambino SR. Beyond normality: the predictive value and efficiency of medical diagnoses. New York: Wiley, 1972.
17. Sokal RR, Rohlf FJ. Biometry. The principle and practice of statistics in biological research. San Francisco: Freeman, 1981.
18. Seccamani E, Tattanelli M, Mariani M, Spranzi E, Scassellati GA, Siccardi AG. A simple qualitative determination of human antibodies to murine immunoglobulins (HAMA) in serum samples. Nucl Med Biol 1989; 2: 167-170.
19. Lamberts SWJ, Bakker WH, Reubi JC, Krenning EP. Somatostatin-receptor imaging in the localization of endocrine tumors. N Engl J Med 1990; 323: 1246-1249.
20. Kwekkeboom DJ, Krenning EP, Bakker WH, Oei HY, Splinter TAW, Siang Kho G, Lamberts SWJ. Somatostatin analogue scintigraphy in carcinoid tumours. Eur J Nucl Med 1993; 20: 283-292.
21. Sobol RE, Memoll V, Deftos LJ. Hormone-negative, chromogranin A-positive endocrine tumors. N Engl J Med 1989; 320: 444-447.
22. Welt S, Mattes MJ, Grando R, Thomson TM, Leonard RW, Zanzonico PB, Bigler RE, Yeh S, Oettgen HF, Old LJ. Monoclonal antibody to an intracellular antigen images human melanoma transplants in nu/nu mice. Proc Natl Acad Sci USA 1987; 84: 4200-4204.
23. Khaw BA, Gold HK, Yasuda T, Leinbach RC, Kanke M, Fallon JT, Barlai-Kovach M, Strauss HW, Sheehan F, Haber E. Scintigraphic quantification of myocardial necrosis in patients after intravenous injection of myosin-specific antibody. Circulation 1986; 74: 501-508.